

# Division of Dermatology, Grand

**October 1, 2024 at 8:00 AM – 9:00 AM**

**UCLA Ronald Reagan Medical Center**

## **Division of Dermatology, Grand Rounds - 10/1/2024**

### **Overview**

The UCLA Dermatology Grand Rounds is the core meeting of the division. This series trains attendees to evaluate and manage challenging patients. It provides an opportunity for presentation of challenging patients from the division. Attendees are exposed to cutting-edge basic science and clinical research. The latest literature is reviewed, keeping attendees up to date on issues such as pathogenesis, therapeutics, epidemiology, patient safety, and clinical competency. It invites nationally and internationally renowned speakers to expose the audience to outside expertise. It serves as a resource for the audience to keep current on knowledge, competency, and clinical practice in order to better serve patients with skin diseases.

Objective(s): 1 Generate appropriate differential diagnoses of live patients presented. 2 Interpret laboratory and histological information, including review of pathology slides from skin biopsies taken from presented patients. 3 Provide management guidance to the physician presenting the patient. 4 Follow-up on patients presented in prior case reviews. 5 Describe current basic-science research in dermatology. 6 Discuss current clinical research in dermatology. 7 Review and analyze the etiology, pathogenesis and therapy of dermatologic topics. 8 Discuss the use of new technology in dermatology and utilize appropriately. 9 Improve patient outcomes. 10 Improve clinical practice. 11 Provide board-relevant information to residents.

Location: UCLA Ronald Reagan Medical Center

Specialties: Dermatology, Dermatopathology, General Dermatology, Micrographic Dermatologic Surgery, Pediatric Dermatology

### **Faculty Disclosures:**

Lindsay Ackerman, MD (Other: Advisory Board, Consultant, Investigator, Speaker-AbbVie|Other: Investigator, Speaker-Amgen|Other: Investigator-Appollo Therapeutics Ltd|Other: Investigator, Speaker-arGEN-X|Other: Investigator-AstraZeneca|Other: Advisory Board-Biofrontera AG|Other: Advisory Board, Investigator, Speaker-Bristol-Myers Squibb|Other: Investigator-Castle Biosciences|Other: Investigator-ChemoCentryx|Other: Investigator-CorEvitas|Other: Investigator-Corronea, Inc.|Other: Investigator-DermTech International|Other: Advisory Board, Investigator, Speaker-Eli Lilly|Other: Investigator-Exact Science|Other: Investigator-GlaxoSmithKline Immunology |Other: Speaker-Helsinn Healthcare|Other: Investigator-IgGenix, Inc|Other: Investigator-Incyte Corporation|Other: Advisory Board-Janssen Pharmaceuticals, Inc|Other: Investigator-Kymera Therapeutics|Other: Speaker-Kyowa Kirin|Other: Investigator-LEO Laboratories Ltd|Other: Advisory Board, Speaker-Lilly ICOS LLC|Other: Investigator-Mindera|Other: Advisory Board-Novartis|Other: Investigator-Regeneron|Other: Investigator-Replimune|Other: Advisory Board, Investigator-Sanofi|Other: Investigator, Speaker-Sun Pharmaceutical Industries Ltd|Other: Investigator-Takeda Pharmaceuticals USA Inc|Other: Advisory Board, Consultant, Investigator-Timber Pharmaceuticals|Other: Investigator-Trevi Therapeutics|Other: Advisory Board, Investigator-UCB - 09/20/2024)

Erin Collier, MD (Nothing to disclose - 03/12/2024)

Ryan Carlisle, MD (Nothing to disclose - 02/23/2024)

Omeed Modiri, MD (Nothing to disclose - 04/09/2024)

[Download Handout](#)

### **Learning Objectives**

- 1 Generate appropriate differential diagnoses of live patients presented.
- 2 Interpret laboratory and histological information, including review of pathology slides from skin biopsies taken from presented patients.
- 3 Provide management guidance to the physician presenting the patient.
- 4 Follow-up on patients presented in prior case reviews.
- 5 Describe current basic-science research in dermatology.

- 6 Discuss current clinical research in dermatology.
- 7 Review and analyze the etiology, pathogenesis and therapy of dermatologic topics.
- 8 Discuss the use of new technology in dermatology and utilize appropriately.
- 9 Improve patient outcomes.
- 10 Improve clinical practice.
- 11 Provide board-relevant information to residents.

## Target Audience

Specialties – Dermatology, Dermatopathology, General Dermatology, Micrographic Dermatologic Surgery, Pediatric Dermatology  
Professions – Physician, Fellow, Laboratory, Resident, Scientist/ Researcher

## Accreditation Statement



ACCME  
ACCREDITED

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## Credit Designation Statements

The David Geffen School of Medicine at UCLA designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Disclosure Statement

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Marcia Hogeling, MD	Activity Administrator	Nothing to disclose - 02/09/2024
Kyle Cheng, MD	Course Director	Stocks or stock options, excluding diversified mutual funds-Cabaletta Consulting Fee-Boehringer Ingelheim Pharmaceuticals, Inc. (Relationship has ended) Stocks or stock options, excluding diversified mutual funds-Arcutis - 01/26/2024
Christopher Song, BA	Activity Administrator	Nothing to disclose - 01/26/2024
Julie Lopez, Other	Activity Administrator	Nothing to disclose - 01/11/2024
Kimberly Valencia	CCPD Staff	Nothing to disclose - 08/27/2024
Ryan Carlisle, MD	Faculty	Nothing to disclose - 02/23/2024
Omeed Modiri, MD, Resident	Faculty	Nothing to disclose - 04/09/2024
Erin Collier, MD	Faculty	Nothing to disclose - 03/12/2024
Lindsay Ackerman, MD	Faculty	Other: Advisory Board, Consultant, Investigator, Speaker-AbbVie Other: Investigator, Speaker-Amgen Other: Investigator-Appollo Therapeutics Ltd Other: Investigator, Speaker-arGEN-X Other: Investigator-AstraZeneca Other: Advisory Board-Biofrontera AG Other: Advisory Board, Investigator, Speaker-Bristol-Myers Squibb Other: Investigator-Castle Biosciences Other: Investigator-ChemoCentryx Other: Investigator-CorEvitas Other: Investigator-Corronea, Inc. Other: Investigator-DermTech International Other: Advisory Board, Investigator, Speaker-Eli

		Lilly  Other: Investigator-Exact Science  Other: Investigator-GlaxoSmithSkline Immunology   Other: Speaker-Helsinn Healthcare  Other: Investigator-IgGenix, Inc  Other: Investigator-Incyte Corporation  Other: Advisory Board-Janssen Pharmaceuticals, Inc  Other: Investigator-Kymera Therapeutics  Other: Speaker-Kyowa Kirin  Other: Investigator-LEO Laboratories Ltd  Other: Advisory Board, Speaker-Lilly ICOS LLC  Other: Investigator-Mindera  Other: Advisory Board-Novartis  Other: Investigator-Regeneron  Other: Investigator-Replimune  Other: Advisory Board, Investigator-Sanofi  Other: Investigator, Speaker-Sun Pharmaceutical Industries Ltd  Other: Investigator-Takeda Pharmaceuticals USA Inc  Other: Advisory Board, Consultant, Investigator-Timber Pharmaceuticals  Other: Investigator-Trevi Therapeutics  Other: Advisory Board, Investigator-UCB - 09/20/2024
Abigail Katz, BA	Faculty	Nothing to disclose - 09/26/2024

**Commercial Support**

This activity has not received commercial support.

**Connect with Us**

Center for Continuing Medical Education (CCPD)  
[ccpd@mednet.ucla.edu](mailto:ccpd@mednet.ucla.edu)  
 (310) 794-2620